Short name: CMC 001, central moiety: Mn2+
CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract. Applications are screening of liver tumors/metastases, imaging of the biliary tract and it could be suitable for liver function studies by following the metabolism and excretion of manganese in the liver cells. Several advantages like better images, higher safety, lower costs and less inconvenience for the patient can be expected.
Animal experiments and clinical studies in humans Phase I and Phase II A, have shown excellent contrast enhancing properties with only minimal adverse effects. CMC 001 is under development by the Medicon Valley based CMC Contrast AB to receive a cost effective, safe and highly diagnostic MR contrast medium for abdominal MR imaging. Clinical studies in Phase III are started.

Quick Overview

Pulsatile cerebro spinal fluid flow produces ghost artifacts that are superimposed in the image.

Flow compensation should be used to reduce these artifacts. This applies an additional gradient to eliminate phase differences for both stationary and moving spins at the echo time. At TE no phase differences is measured. If flow compensation is applied and there are still flow artifacts, cardiac triggering is an additional option to reduce these artifacts.
See also Motion Artifact.

Quick Overview
Please note that there are different common names for this artifact.

During frequency encoding, fat protons precess slower than water protons in the same slice because of their magnetic shielding. Through the difference in resonance frequency between water and fat, protons at the same location are misregistrated (dislocated) by the Fourier transformation, when converting MRI signals from frequency to spatial domain. This chemical shift misregistration cause accentuation of any fat-water interfaces along the frequency axis and may be mistaken for pathology. Where fat and water are in the same location, this artifact can be seen as a bright or dark band at the edge of the anatomy.
Protons in fat and water molecules are separated by a chemical shift of about 3.5 ppm. The actual shift in Hertz (Hz) depends on the magnetic field strength of the magnet being used. Higher field strength increases the misregistration, while in contrast a higher gradient strength has a positive effect. For a 0.3 T system operating at 12.8 MHz the shift will be 44.8 Hz compared with a 223.6 Hz shift for a 1.5 T system operating at 63.9 MHz.

For artifact reduction helps a smaller water fat shift (higher bandwidth), a higher matrix, an in phase TE or a spin echo technique. Since the misregistration offset is present in the read out axis the patient may be rescanned with this axis parallel to the fat-water interface. Steeper gradient may be employed to reduce the chemical shift offset in mm. Another strategy is to employ specialized pulse sequences such as fat saturation or inversion recovery imaging. Fat suppression techniques eliminate chemical shift artifacts caused by the lack of fat signal.

See also Black Boundary Artifact and Magnetic Resonance Spectroscopy.

Quick Overview

A combination of B1 inhomogeneity, poor slice profile, and insufficient spoiler gradients between the refocusing pulse and the readout interval of a spin echo sequence results in a FID signal being detected along with the echo.
Since the FID is not phase encoded (normally the phase encoding occurs before the refocusing pulse), it is not dispersed along the phase encoding axis, but appears as a line across the center of the image.

If the problem persists, it must be addressed by a service representative.

FSE optimization runs a preliminary TR period at the central slice and compares the phase of each echo in the echo train. If the phases do not compliment each other the RF is recalibrated and then the entire sequence is run. If there is an error in calibrating the phases of each of the echoes artifacts will appear.